Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls | Zendy

M. Holtze | Zendy; Peter Saetre | Zendy; Göran Engberg | Zendy; Lilly Schwieler | Zendy; Thomas Werge | Zendy; Ole A. Andreassen | Zendy; Håkan Hall | Zendy; Lars Terenius | Zendy; Ingrid Agartz | Zendy; Erik G. Jönsson | Zendy; Martin Schalling | Zendy; Sophie Erhardt | Zendy

Open Access

Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls

Author(s) -

M. Holtze,

Peter Saetre,

Göran Engberg,

Lilly Schwieler,

Thomas Werge,

Ole A. Andreassen,

Håkan Hall,

Lars Terenius,

Ingrid Agartz,

Erik G. Jönsson,

Martin Schalling,

Sophie Erhardt

Publication year - 2011

Publication title -

journal of psychiatry and neuroscience

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.767

H-Index - 99

eISSN - 1488-2434

pISSN - 1180-4882

DOI - 10.1503/jpn.100175

Subject(s) - kynurenic acid , kynurenine , kynurenine pathway , single nucleotide polymorphism , haloperidol , schizophrenia (object oriented programming) , medicine , metabolite , snp , pharmacology , endocrinology , nmda receptor , chemistry , psychology , biochemistry , receptor , dopamine , amino acid , psychiatry , tryptophan , gene , genotype

Patients with schizophrenia show increased brain and cerebrospinal fluid (CSF) concentrations of the endogenous N-methyl-D-aspartate receptor antagonist kynurenic acid (KYNA). This compound is an end-metabolite of the kynurenine pathway, and its formation indirectly depends on the activity of kynurenine 3-monooxygenase (KMO), the enzyme converting kynurenine to 3-hydroxykynurenine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research